drugset / Trial / NCT00963183

AZD5423 Single Ascending Dose Study

NCT00963183

Phase 1 Completed 72 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindBasic science

Summary

The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5423 following single ascending dose administrations in healthy male subjects.

Timeline

Start
2009-08
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5423 Other / unclassified 8.4 ug Inhaled

Indications

No indication recorded.